Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused

Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still high in many countries. Monoclonal antibodies against SARS-CoV-2 are the ideal complement to vaccination in infected subjects who are at high risk for progression to sev...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ivan Gentile, Alberto Enrico Maraolo, Antonio Riccardo Buonomo, Mariano Nobile, Prisco Piscitelli, Alessandro Miani, Nicola Schiano Moriello
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 monoclonal antibodies lethality hospitalizations savings Medicine R
Acceso en línea:	https://doaj.org/article/b7fb01da7b214bbf9105986b0f8ace84
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b7fb01da7b214bbf9105986b0f8ace84
record_format	dspace
spelling	oai:doaj.org-article:b7fb01da7b214bbf9105986b0f8ace842021-11-11T16:18:44ZMonoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused10.3390/ijerph1821111591660-46011661-7827https://doaj.org/article/b7fb01da7b214bbf9105986b0f8ace842021-10-01T00:00:00Zhttps://www.mdpi.com/1660-4601/18/21/11159https://doaj.org/toc/1661-7827https://doaj.org/toc/1660-4601Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still high in many countries. Monoclonal antibodies against SARS-CoV-2 are the ideal complement to vaccination in infected subjects who are at high risk for progression to severe disease. Based on data of the Italian Ministry of Health, in the period April–August 2021, monoclonal antibodies were prescribed to 6322 patients. In the same period, 70,022 patients over 70 years old became infected with SARS-CoV-2. Even considering that all monoclonal antibodies were prescribed to this category of patients, we calculated that only 9% of these subjects received the treatment. Moreover, using efficacy data provided by clinal trials, we estimated the potential benefit in terms of reduction of hospital admissions and deaths. Considering utilisation of monoclonal antibodies in half infected patients over 70 years, we estimated that hospital admissions and deaths might have been reduced by 7666 and 3507, respectively. Finally, we calculated the economic benefit of monoclonal use. In the same scenario (50% use of monoclonal antibodies to patients over 70), we estimated potential savings of USD 117,410,105. In conclusion, monoclonal antibodies were used in a small proportion of patients over 70 in Italy. A more extensive use might have resulted in a marked decrease in hospital admissions, deaths and in conspicuous saving for the health system.Ivan GentileAlberto Enrico MaraoloAntonio Riccardo BuonomoMariano NobilePrisco PiscitelliAlessandro MianiNicola Schiano MorielloMDPI AGarticleCOVID-19monoclonal antibodieslethalityhospitalizationssavingsMedicineRENInternational Journal of Environmental Research and Public Health, Vol 18, Iss 11159, p 11159 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 monoclonal antibodies lethality hospitalizations savings Medicine R
spellingShingle	COVID-19 monoclonal antibodies lethality hospitalizations savings Medicine R Ivan Gentile Alberto Enrico Maraolo Antonio Riccardo Buonomo Mariano Nobile Prisco Piscitelli Alessandro Miani Nicola Schiano Moriello Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
description	Even several months after the start of a massive vaccination campaign against COVID-19, mortality and hospital admission are still high in many countries. Monoclonal antibodies against SARS-CoV-2 are the ideal complement to vaccination in infected subjects who are at high risk for progression to severe disease. Based on data of the Italian Ministry of Health, in the period April–August 2021, monoclonal antibodies were prescribed to 6322 patients. In the same period, 70,022 patients over 70 years old became infected with SARS-CoV-2. Even considering that all monoclonal antibodies were prescribed to this category of patients, we calculated that only 9% of these subjects received the treatment. Moreover, using efficacy data provided by clinal trials, we estimated the potential benefit in terms of reduction of hospital admissions and deaths. Considering utilisation of monoclonal antibodies in half infected patients over 70 years, we estimated that hospital admissions and deaths might have been reduced by 7666 and 3507, respectively. Finally, we calculated the economic benefit of monoclonal use. In the same scenario (50% use of monoclonal antibodies to patients over 70), we estimated potential savings of USD 117,410,105. In conclusion, monoclonal antibodies were used in a small proportion of patients over 70 in Italy. A more extensive use might have resulted in a marked decrease in hospital admissions, deaths and in conspicuous saving for the health system.
format	article
author	Ivan Gentile Alberto Enrico Maraolo Antonio Riccardo Buonomo Mariano Nobile Prisco Piscitelli Alessandro Miani Nicola Schiano Moriello
author_facet	Ivan Gentile Alberto Enrico Maraolo Antonio Riccardo Buonomo Mariano Nobile Prisco Piscitelli Alessandro Miani Nicola Schiano Moriello
author_sort	Ivan Gentile
title	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
title_short	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
title_full	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
title_fullStr	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
title_full_unstemmed	Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
title_sort	monoclonal antibodies against sars-cov-2: potential game-changer still underused
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/b7fb01da7b214bbf9105986b0f8ace84
work_keys_str_mv	AT ivangentile monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT albertoenricomaraolo monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT antonioriccardobuonomo monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT marianonobile monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT priscopiscitelli monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT alessandromiani monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused AT nicolaschianomoriello monoclonalantibodiesagainstsarscov2potentialgamechangerstillunderused
_version_	1718432378762821632

Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused

Ejemplares similares